Uveitis is a spectrum of inflammatory disorders developed by ocular inflammation. It is one of the major causes of visual loss and it is preventable.
Uveitis is a spectrum of inflammatory disorders developed by ocular inflammation. It is one of the major causes of visual loss and it is preventable. The prime aim of the treatment of uveitis is to prevent recurrences of the diseases, control the inflammation, and preserve vision while minimizing the harmful effects associated with therapeutic agents. The initial management of uveitis depends on the use of corticosteroids but there are some side effects that cannot be managed in long term. Thus, there is a constant search for novel drugs and implants that can treat severe cases of uveitis and help patients gain their sight back.
The growth of the uveitis market is attributed to rise in prevalence of uveitis disorders across the globe. Furthermore, growth in treatment awareness and rise in adoption of uveitis treatments contribute to the growth of the market.
According to Allied Market Research, the global uveitis treatment market is expected to reach $687 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026. Rise in prevalence of uveitis, increase in healthcare expenditure across the globe, and potential drugs in the pipeline have boosted the growth of the market. Rise in the launch of new treatments has also opened new opportunities in the industry.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/6359
Uveitis is characterized by inflammation of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. Different types of medication such as cycloplegic agents, anti-inflammatory, and immunotherapy & targeted therapies, antimicrobial drugs, and others are used in the treatment of uveitis.
Recently, Alimera Science, Inc., a global pharmaceutical company, has announced to launch ILUVIEN for non-infectious posterior uveitis in Spain via Brill Pharma, its distribution partner. Not long ago, Brill received a positive resolution for reimbursement and pricing approval for ILUVIEN, especially for the prevention of relapse in non-infectious, recurrent uveitis which affects the posterior segment of the eye. ILUVIEN is an intravitreal implant for the treatment of vision impairment associated with severe diabetic macular edema (DME).
The uveitis treatment market is expected to experience significant growth during the forecast period, owing to rise in demand for uveitis treatment medication across geographies with increase in popularity advanced therapeutics. Furthermore, increase in prevalence of uveitis with early detection further boost the uveitis treatment market growth during the forecast period. However, lack of adverse effects associated with the use of drugs may hamper the market growth.
Similarly, Bausch + Lomb, a leading market player in the uveitis treatment market, announced the launch of XIPERE, which is a triamcinolone acetonide injectable suspension. XIPERE is the only therapy that is approved by the U.S. Food and Drug Administration for suprachoroidal use and for the treatment of macular edema related to uveitis. As macular edema causes distorted vision and retinal swelling, it may lead to permanent vision loss if left untreated. Thus, the new treatment method is launched for macular edema via suprachoroidal administration with the use of an SCS microinjector.
Such new treatments have decreased the number of annual visits to hospitals for uveitis. In the future, such treatment would make uveitis treatable and less threatening. Moreover, the use of biosensors and Internet of Things (IoT) is expected to improve treatments of uveitis. The sensors would transmit the critical levels of cytokines and other inflammatory mediators throughout the eye and inform the specialists. Such technological innovations would transform conventional uveitis treatments drastically.